Clinical trials: Pulmonary Artery Hypertension
Pulmonary Hypertension, Systemic Sclerosis
Early Therapy of Pulmonary Arterial Hypertension
Exercise-induced increase of the pulmonary arterial pressure may be an early sign of pulmonary arterial hypertension. It has been shown that patients with normal pulmonary arterial pressure at rest but elevated pulmonary arterial…
- Trial name
- NCT00909337
- Testing
- Bosentan
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Graz
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Hypertension, Pulmonary Artery Pressure
Does Sildenafil Increase Exercise Performance in Air Pollution?
The purpose of this study is to examine if the ingestion of a standard dose of sildenafil enhances the athletic performance of competitive athletes when exercising in a high pollutant environment verses a low air pollutant…
- Conditions
- Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
- Trial name
- NCT00808912
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Marywood University
Pulmonary Fibrosis, Pulmonary Hypertension
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure.
- Trial name
- NCT00109681
- Testing
- Iloprost Inhalation Solution (Ventavis)
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Vasodilation
Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)
Endothelin-1 (ET-1) has been linked to a number of conditions including pulmonary arterial hypertension (PAH). ET-1 acts via 2 receptors, ETA and ETB.
- Conditions
- Pulmonary Arterial Hypertension, Vasodilation, Vasoconstriction
- Trial name
- NCT01100736
- Testing
- Bosentan, Sitaxsentan, Endothelin-3
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Pulmonary Arterial Hypertension
Beta-blockers in Pulmonary Arterial Hypertension
The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection…
- Trial name
- NCT02507011
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Minnesota
Pulmonary Arterial Hypertension
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph).
- Trial name
- TRACE (NCT03078907)
- Testing
- Selexipag
- Where
- 39 sites in United States, Austria and 8 more
- Volunteers
- 108 people
- Sponsor
- Actelion
Pulmonary Hypertension
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00080457
- Testing
- sitaxsentan sodium
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Encysive Pharmaceuticals
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance 6MWD Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito: 2850m) to sea level on six-minute walking distance and scores in patients with pulmonary arterial hypertension PAH, who live permanently >2600m.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, High Altitude Effects
- Trial name
- NCT07804472
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Acne Vulgaris, Allergic Rhinitis
MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use
The specific aim of this proposed pilot study is to compare two standardized processes (paper and electronic) to deliver a customized MedlinePlus health information prescription.
- Conditions
- Acne Vulgaris, Allergic Rhinitis, Anxiety, Asthma
- Trial name
- NCT01050465
- Testing
- health information prescription
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Pulmonary Hypertension and Anastrozole Trial
The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in…
- Trial name
- PHANTOM (NCT03229499)
- Testing
- Anastrozole
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- University of Pennsylvania
Hypertension, Pulmonary
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
The MOTION study was a prospective, Phase IV study for patients with Pulmonary Arterial Hypertension (PAH). The study was designed to further explore patient-reported outcomes in PAH subjects who were not on active treatment and…
- Trial name
- NCT02191137
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 59 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Bayer
Cardiovascular Diseases, Heart Diseases
Strong Heart Study
To determine morbidity and mortality from cardiovascular disease among American Indians and to compare cardiovascular disease risk factor levels among Indian groups living in different geographic areas.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Asthma
- Trial name
- NCT00005134
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Oxygen Deficiency, Pulmonary Arterial Hypertension
The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia
Treatment of O2 naïve patients with PAH will be included in this investigator-initiated trial (IIT) to assess efficacy and safety of oxygen substitution.
- Conditions
- Oxygen Deficiency, Pulmonary Arterial Hypertension, CTEPH
- Trial name
- SOPHA (NCT04207593)
- Testing
- Oxygen
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Eisenmenger Complex
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome
In this study, the investigator will evaluate the treatment effects and safety, patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan.
- Trial name
- NCT04732650
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Pulmonary Arterial Hypertension
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
The purpose of the study is to evaluate the safety and tolerability of a rapid dose titration regimen of subcutaneous Remodulin® therapy in patients with PAH.
- Trial name
- RAPID (NCT02847260)
- Testing
- Remodulin
- Volunteers
- 39 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Hypertensive Disorder of Pregnancy, Pulmonary Arterial Hypertension
A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
In this study, the investigators will follow two small cohorts of pregnant women: a cohort of healthy women with uncomplicated pregnancies residing at high altitude, a control group of healthy women with uncomplicated pregnancies…
- Conditions
- Hypertensive Disorder of Pregnancy, Pulmonary Arterial Hypertension, Intrauterine Growth Restriction
- Trial name
- NCT07312227
- Where
- 2 sites in United States, Bolivia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Pulmonary Arterial Hypertension
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
IMPAHCT-FUL: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (LTE) Trial was a follow up study to establish the long-term safety of AV-101.
- Trial name
- IMPAHCT-FUL (NCT05557942)
- Testing
- AV-101
- Where
- 72 sites in United States, Argentina and 18 more
- Volunteers
- 186 people
- Sponsor
- Aerovate Therapeutics